Daniel A. Pryor
Net Worth

Last updated:

What is Daniel A. Pryor net worth?

The estimated net worth of Mr. Daniel A. Pryor is at least $64,805,869 as of 6 Sep 2025. He owns shares worth $37,008,947 as insider, has earned $9,404,922 from insider trading and has received compensation worth at least $18,392,000 in companies like Enovis Corporation, Colfax Corporation, Colfax Corporation etc.

What is the salary of Daniel A. Pryor?

Mr. Daniel A. Pryor salary is $1,130,000 per year as Executive Vice President of Strategy & Bus. Devel. in Enovis Corporation. He also receives $959,000 as Executive Vice President of Strategy & Bus. Devel. in Colfax Corporation and salaries from other companies.

How old is Daniel A. Pryor?

Mr. Daniel A. Pryor is 57 years old, born in 1968.

What stocks does Daniel A. Pryor currently own?

As insider, Mr. Daniel A. Pryor owns shares in 2 companies:

Company Title Shares Price per share Total value
Colfax Corporation (CFX) Executive Vice President of Strategy & Bus. Devel. 200,175 $39.06 $7,818,836
Colfax Corporation (CFXA) Executive Vice President of Strategy & Bus. Devel. 164,257 $177.71 $29,190,111

What does Colfax Corporation do?

Colfax Corporation operates as a diversified technology company worldwide. The company operates in two segments, Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment for use in cutting, joining, and automated welding, as well as gas control equipment. It also provides welding consumables comprising electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, such as electrodes, nozzles, and shields and tips. This segment sells its products through independent distributors and direct sales to the general industry, construction, infrastructure, transportation, energy, renewable energy, and medical and life sciences markets principally under the ESAB brand. The Medical Technology segment develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. This segment sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. Colfax Corporation was founded in 1860 and is headquartered in Wilmington, Delaware.

What does Colfax Corporation do?

Colfax Corporation operates as a diversified technology company worldwide. The company operates in two segments, Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment, including cutting, joining, and automated welding products, as well as gas control equipment. It also provides welding consumables comprising electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, such as electrodes, nozzles, and shields and tips. This segment sells its products through independent distributors and direct sales to the infrastructure, wind power, marine/life sciences, pipelines, mobile/off-highway equipment, oil, gas, and mining markets principally under the ESAB brand. The Medical Technology segment develops, manufactures, and distributes medical device products used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. This segment sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and direct and independent distributors under the DJO brand. Colfax Corporation was founded in 1860 and is based in Wilmington, Delaware.

Daniel A. Pryor insider trading

Colfax Corporation

Mr. Daniel A. Pryor has made 15 insider trades between 2011-2022, according to the Form 4 filled with the SEC. Most recently he sold 3,463 units of CFX stock worth $134,641 on 7 Mar 2022.

The largest trade he's ever made was exercising 53,333 units of CFX stock on 19 Dec 2017. As of 6 Sep 2025 he still owns at least 200,175 units of CFX stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common stock, par value $.001 3,463 $38.88 $134,641
Sale
Common stock, par value $.001 31,274 $41.18 $1,287,895
Sale
Common stock, par value $.001 2,024 $42.18 $85,372
Sale
Common stock, par value $.001 1,866 $41.83 $78,055
Option
Employee Stock Option (right to buy) 556 $52.02 $28,923
Sale
Common stock, par value $.001 556 $53.03 $29,486
Option
Common stock, par value $.001 556 $52.02 $28,923
Option
Common stock, par value $.001 7,289 $52.02 $379,174
Sale
Common stock, par value $.001 7,289 $53.91 $392,979
Option
Employee Stock Option (right to buy) 23,905 $52.02 $1,243,538
Option
Common stock, par value $.001 16,616 $52.02 $864,364
Sale
Common stock, par value $.001 16,616 $53.94 $896,267
Option
Employee Stock Option (right to buy) 6,340 $52.02 $329,807
Sale
Common stock, par value $.001 6,340 $53.02 $336,153
Option
Common stock, par value $.001 6,340 $52.02 $329,807
Sale
Common stock, par value $.001 36,062 $35.65 $1,285,718
Sale
Common stock, par value $.001 1,961 N/A N/A
Sale
Common Stock, par value $.001 4,825 $33.32 $160,764
Option
Common Stock, par value $.001 17,226 $21.77 $375,010
Option
Employee Stock Option (right to buy) 17,226 $21.77 $375,010
Sale
Common Stock, par value $.001 1,682 $33.46 $56,283
Option
Employee Stock Option (right to buy) 53,333 $18.75 $999,994
Option
Common Stock, par value $.001 53,333 $18.75 $999,994
Sale
Common Stock, par value $.001 53,333 $18.75 $999,994
Sale
Common Stock, par value $.001 3,574 $41.13 $146,981
Sale
Common Stock, par value $.001 1,363 $38.17 $52,022
Purchase
Common Stock, par value $.001 3,000 $63.26 $189,774
Purchase
Common Stock, par value $.001 2,000 $23.91 $47,822

Colfax Corporation

Mr. Daniel A. Pryor has made 6 insider trades in 2021, according to the Form 4 filled with the SEC. Most recently he sold 556 units of CFXA stock worth $29,486 on 8 Nov 2021.

The largest trade he's ever made was exercising 36,062 units of CFXA stock on 10 Mar 2021. As of 6 Sep 2025 he still owns at least 164,257 units of CFXA stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common stock, par value $.001 556 $53.03 $29,486
Option
Employee Stock Option (right to buy) 556 $52.02 $28,923
Option
Common stock, par value $.001 556 $52.02 $28,923
Option
Employee Stock Option (right to buy) 23,905 $52.02 $1,243,538
Sale
Common stock, par value $.001 7,289 $53.91 $392,979
Option
Common stock, par value $.001 7,289 $52.02 $379,174
Sale
Common stock, par value $.001 16,616 $53.94 $896,267
Option
Common stock, par value $.001 16,616 $52.02 $864,364
Sale
Common stock, par value $.001 6,340 $53.02 $336,153
Option
Common stock, par value $.001 6,340 $52.02 $329,807
Option
Employee Stock Option (right to buy) 6,340 $52.02 $329,807
Sale
Common stock, par value $.001 36,062 $47.62 $1,717,200
Sale
Common stock, par value $.001 1,961 $46.01 $90,226

Enovis key executives

Enovis Corporation executives and other stock owners filed with the SEC:

  • Mr. Bradley J. Tandy Senior Vice President, Gen. Counsel & Sec.
  • Mr. Brady R. Shirley (59) Chief Executive Officer of DJO & Executive Vice President
  • Mr. Christopher M. Hix (63) Executive Vice President of Fin. & Chief Financial Officer
  • Mr. Daniel A. Pryor (57) Executive Vice President of Strategy & Bus. Devel.
  • Mr. Matthew L. Trerotola (58) Pres, Chief Executive Officer & Director
  • Mr. Mitchell P. Rales (68) Co-Founder & Chairman
  • Mr. Shyam Kambeyanda (54) Executive Vice President and Chief Executive Officer & Pres of ESAB
  • Mr. Steven L. Breitzka Interim Senior Vice President of Global Operations & Americas
  • Mr. Terry Ross Vice President of Investor Relations, Strategy & Bus. Devel.
  • Ms. Patricia A. Lang Senior Vice President & Chief HR Officer